PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 14, 2015Science Translational Medicine447 citationsOpen Access

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

View Full Paper
JNJoan O. NgwutaMCMan ChenKMKayvon Modjarrad

Key Points

Key points are not available for this paper at this time.

Abstract

Respiratory syncytial virus (RSV) is estimated to claim more lives among infants 90% of NT activity and depleted binding antibodies to both F conformations. In contrast, adsorption with post-F removed ~30% of NT activity, and binding antibodies to pre-F were retained. These findings were consistent across all age groups. Protein competition neutralization assays with pre-F mutants in which sites Ø or II were altered to knock out binding of antibodies to the corresponding sites showed that these sites accounted for ~35 and <10% of NT activity, respectively. Binding competition assays with monoclonal antibodies (mAbs) indicated that the amount of site Ø-specific antibodies correlated with NT activity, whereas the magnitude of binding competed by site II mAbs did not correlate with neutralization. Our results indicate that RSV NT activity in human sera is primarily derived from pre-F-specific antibodies, and therefore, inducing or boosting NT activity by vaccination will be facilitated by using pre-F antigens that preserve site Ø.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ngwuta et al. (2015) studied this question.

synapsesocial.com/papers/69d89b76de3177251abedbbdhttps://doi.org/10.1126/scitranslmed.aac4241
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Generation of stable monoclonal antibody–producing B cell receptor–positive human memory B cells by genetic programming2009 · 310 citations
  2. 2Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults2005 · 2,266 citations
  3. 3Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies1992 · 120 citations
  4. 4Palivizumab for the prevention of respiratory syncytial virus infection.2010 · 44 citations
  5. 5Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention2012 · 274 citations